MedTrace Logo

Prophylactic Treatment With Oseltamivir

NCT03899571 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2020-11-03

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.

Conditions

  • Influenza, Human

Interventions

DRUG

Oseltamivir Oral Capsule for 5 days post-exposure

Patients will receive oseltamivir for 5 days after last influenza exposure.

DRUG

Oseltamivir Oral Capsule for 10 days post-exposure

Patients will receive oseltamivir for 10 days after last influenza exposure.

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899571 on ClinicalTrials.gov